Thorne HealthTech, Inc. (NasdaqGS:THRN) is exploring a sale, according to people familiar with the matter. The New York-based company is working with investment bank CG Sawaya Partners (CF.TO) as it fields interest from other companies and private equity firms, the sources said. Thorne's shares are up 45% year-to-date, outperforming an 18% rise in the S&P 500 Index and giving it a stock market value of around $300 million.

The sources, who asked not to be identified because the matter is confidential, added that no deal is certain. A Thorne spokesperson said the company does not comment on rumors or speculation. CG Sawaya did not respond to requests for comment.